Retatrutide (LY3437943) is a novel triple agonist peptide targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This innovative compound has shown promising results in glucose control and weight management studies for type 2 diabetes research.
Our pharmaceutical-grade Retatrutide is supplied in lyophilized form with purity exceeding 99%, making it ideal for research applications. The peptide is delivered in sterile vials with comprehensive analytical documentation to ensure quality and consistency for your studies.
Key research applications include:
1. Metabolic disorder studies
2. Weight management mechanisms
3. Glucose regulation research
4. Neuroprotective effect investigations
5. Chronic pain management studies
We offer flexible customization options including various vial sizes (2mg to 50mg) and private label packaging solutions. All products are strictly for research purposes only and not for human consumption.
Storage requirements: Maintain at -20°C or below in dry conditions. Proper handling procedures should be followed according to laboratory safety protocols.